Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Purification and characterization of monoclonal IgG antibodies recognizing Ebola virus glycoprotein

  • Han, Baek-Sang (BK21 Plus Graduate Program and Department of Microbiology, Kangwon National University School of Medicine) ;
  • Jang, Ho-Young (BK21 Plus Graduate Program and Department of Microbiology, Kangwon National University School of Medicine) ;
  • Racine, Trina (Centre de Recherche en Infectiologie de l'Universite Laval CHU de Quebec-Universite Laval) ;
  • Qiu, Xiangguo (Department of Medical Microbiology University of Manitoba) ;
  • Sin, Jeong-Im (BK21 Plus Graduate Program and Department of Microbiology, Kangwon National University School of Medicine)
  • Received : 2018.05.29
  • Accepted : 2018.08.01
  • Published : 2018.07.31
⟨ Previous Next ⟩

Abstract

Purpose: The goal of this study was to purify and characterize Ebola virus glycoprotein (GP)-specific IgG antibodies from hybridoma clones. Materials and Methods: For hybridoma production, mice were injected by intramuscular-electroporation with GP DNA vaccines, and boosted with GP vaccines. The spleen cells were used for producing GP-specific hybridoma. Enzyme-linked immunosorbent assay, Western blot assay, flow cytometry, and virus-neutralizing assay were used to test the ability of monoclonal IgG antibodies to recognize GP and neutralize Ebola virus. Results: Twelve hybridomas, the cell supernatants of which displayed GP-binding activity by enzyme-linked immunosorbent assay and the presence of both IgG heavy and light chains by Western blot assay, were chosen as a possible IgG producer. Among these, five clones (C36-1, D11-3, D12-1, D34-2, and E140-2) were identified to secrete monoclonal IgG antibodies. When the monoclonal IgG antibodies from the 5 clones were tested for their antigen specificity, they recognized GP in an antigen-specific and IgG dose-dependent manner. They remained reactive to GP at the lowest tested concentrations (1.953-7.8 ng/mL). In particular, IgG antibodies from clones D11-3, D12-1, and E140-2 recognized the native forms of GP expressed on the cell surface. These antibodies were identified as IgG1, IgG2a, or IgG2b kappa types and appeared to recognize the native forms of GP, but not the denatured forms of GP, as determined by Western blot assay. Despite their GP-binding activity, none of the IgG antibodies neutralized Ebola virus infection in vitro, suggesting that these antibodies are unable to neutralize Ebola virus infection. Conclusion: This study shows that the purified IgG antibodies from 5 clones (C36-1, D11-3, D12-1, D34-2, and E140-2) possess GP-binding activity but not Ebola virus-neutralizing activity.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Roshania R, Mallow M, Dunbar N, et al. Successful implementation of a multicountry clinical surveillance and data collection system for Ebola virus disease in West Africa: findings and lessons learned. Glob Health Sci Pract 2016; 4:394-409. https://doi.org/10.9745/GHSP-D-16-00186
  2. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick and Adelberg's medical microbiology. New York: McGraw-Hill; 2013. p.571-3.
  3. Na W, Park N, Yeom M, Song D. Ebola outbreak in Western Africa 2014: what is going on with Ebola virus? Clin Exp Vaccine Res 2015;4:17-22. https://doi.org/10.7774/cevr.2015.4.1.17
  4. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002;76: 6841-4. https://doi.org/10.1128/JVI.76.13.6841-6844.2002
  5. Ito H, Watanabe S, Sanchez A, Whitt MA, Kawaoka Y. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol 1999;73:8907-12.
  6. Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012;4:138ra81.
  7. Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 2013;3:3365. https://doi.org/10.1038/srep03365
  8. PREVAIL II Writing Group; Multi-National PREVAIL II Study Team, Davey RT Jr, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016;375: 1448-56. https://doi.org/10.1056/NEJMoa1604330
  9. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7. https://doi.org/10.1038/256495a0
  10. Lee SH, Han BS, Choe J, Sin JI. Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production. Clin Exp Vaccine Res 2017;6:135-45. https://doi.org/10.7774/cevr.2017.6.2.135
  11. Harlow E, Lane D. Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1988. p.222-3.
  12. Strasser JE, Arnold RL, Pachuk C, Higgins TJ, Bernstein DI. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J Infect Dis 2000;182: 1304-10. https://doi.org/10.1086/315878
  13. Frame KK, Hu WS. The loss of antibody productivity in continuous culture of hybridoma cells. Biotechnol Bioeng 1990;35:469-76. https://doi.org/10.1002/bit.260350504

Cited by

  1. Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus vol.13, pp.1, 2018, https://doi.org/10.1186/s13000-018-0773-1
  2. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines vol.17, pp.7, 2021, https://doi.org/10.1080/21645515.2020.1866951